Efrain Garcia, MD
Infectious Disease · Miami, FLNPI 1447239496
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,490 of the $16,946 with a category attached, or 67.8%. 17 manufacturers reported payments, led by Viiv Healthcare Company at 47.9% of the total. 2025 is the largest year on record at $4,614, 2.5 times the $1,828 reported in 2019. Among infectious disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 280 payments — averaging $60.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$8K
- Gilead$7K
- Johnson & Johnson$607
- Kowa Pharmaceuticals America, Inc.$454
- Merck$156
- Janssen Products, LP$150
- plus $589 from 11 others
Across 115 payments — averaging $21,405 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$2.3M
- Merck$106K
- Sanofi US Services Inc.$15K
- AstraZeneca$13K
What the payments were for
- Consulting fees$11,49068%
- Speaking & faculty fees$150%
- Food & beverage$5,29131%
- Education$1501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 94 | $8,120 |
| Gilead | 98 | $6,870 |
| Johnson & Johnson | 30 | $607 |
| Kowa Pharmaceuticals America, Inc. | 23 | $454 |
| Merck | 8 | $156 |
| Janssen Products, LP | 2 | $150 |
| EMD Serono, Inc. | 4 | $85 |
| Amarin Pharma, Inc. | 4 | $84 |
| Intuitive Surgical | 1 | $76 |
| Napo Pharmaceuticals Inc | 4 | $71 |
| Amgen | 3 | $62 |
| Melinta Therapeutics, LLC | 3 | $54 |
| Smith+Nephew | 1 | $48 |
| Medtronic | 1 | $33 |
| Mylan Pharmaceuticals Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| GSK | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,946 in reported general payments places this provider in the 90th percentile of 669 infectious disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 272 | $1,181,254 |
| SerostimSomatropin | 25 | $502,539 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 47 | $174,933 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 31 | $149,361 |
| TivicayDolutegravir Sodium | 43 | $125,051 |
| JulucaDolutegravir/Rilpivirine | 33 | $120,894 |
| PrezcobixDarunavir/Cobicistat | 24 | $88,831 |
| CabenuvaCabotegravir/Rilpivirine | 12 | $80,188 |
| DovatoDolutegravir Sodium/Lamivudine | 21 | $63,992 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $49,187 |
| MytesiCrofelemer | 11 | $31,189 |
| MounjaroTirzepatide | 22 | $23,045 |
| VascepaIcosapent Ethyl | 66 | $22,127 |
| ValacyclovirValacyclovir Hcl | 72 | $3,698 |
| Testosterone Cypionate | 65 | $1,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $6,870 | $1,181,254272 claims |
| Viiv Healthcare CompanyTriumeq, Tivicay, Juluca, Cabenuva, Dovato | $8,120 | $565,057156 claims |
| EMD Serono, Inc.Serostim | $85 | $502,53925 claims |
| Janssen Products, LPSymtuza | $150 | $149,36131 claims |
| Johnson & JohnsonPrezcobix | $607 | $88,83124 claims |
| Napo Pharmaceuticals IncMytesi | $71 | $31,18911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 669 infectious disease providers in Florida.
Other infectious disease in Miami
- Douglas BrustMiami$359K
- Dushyantha JayaweeraMiami$98K
- Ricardo FrancoMiami$96K
- Lilian AbboMiami$61K
- Jorge MurilloMiami$53K
- Thomas HootonMiami$42K
- Gilberto Torres-MadrizMiami$42K
- Vanessa SilebiMiami$32K
- Hector BolivarMiami$25K
- Jose Camargo GalvisMiami$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.